PRODUCT OVERVIEW
NanoSphere’s initial product deployment is for the cannabinoid market, targeting both the medical marijuana market and, where legalized, the recreational usage market. NanoSphere has already partnered with a licensee in Colorado, and has launched its first award-winning cannabinoid product line, branded Evolve NanoSerum™, in the Colorado market. NanoSphere will further license its intellectual property and proprietary manufacturing method to selected cannabis cultivators, extractors and distributors on a state-by-state basis and abroad, and is currently in discussions with operators in several states to replicate the business model in Colorado. Other planned future deployments include nutraceuticals, non steroidal anti-inflammatory drugs and animal health applications.
272
PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.
PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.
NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.
Q& A
PRODUCT OVERVIEW
NanoSphere’s initial product deployment is for the cannabinoid market, targeting both the medical marijuana market and, where legalized, the recreational usage market. NanoSphere has already partnered with a licensee in Colorado, and has launched its first award-winning cannabinoid product line, branded Evolve NanoSerum™, in the Colorado market. NanoSphere will further license its intellectual property and proprietary manufacturing method to selected cannabis cultivators, extractors and distributors on a state-by-state basis and abroad, and is currently in discussions with operators in several states to replicate the business model in Colorado. Other planned future deployments include nutraceuticals, non steroidal anti-inflammatory drugs and animal health applications.
NSHSF continued: We’re just breaking into the industry, so the opportunity for growth is quite large. You can trust in us because we actually back up what we’re saying with scientific, clinically proven data. Our NanoSphere team is made up of experienced business people that know how to market, drive companies, and build brands. So not only do we have the science down, but we also have the business side down. I think that’s a real reason that investors can trust with us. Plus, the value of the IP alone is of significant worth.
CI: How many shares are outstanding? What is your float? What is your stock price? What is your market cap?
NSHSF:
Issues & outstanding: 96,070,546
Reserved for issuance: 9,781,790
Price: $0.55 (as of April 2nd, 2018)
CI: Your average daily stock liquidity is only approximately $13,000, how do you plan on increasing investor interest in NanoSphere Health Sciences?
NSHSF: We purposely held it in and wanted to assess the market. We plan to release more shares for a more robust trading activity in short order.
CI: Currently you’re a Grey Market Security and not traded on the OTCQX, OTCQB or Pink markets. Do you have any plans on up-listing on the OTC?
NSHSF: Yes, we are on the grey and but we are taking necessary steps to upgrade to the OTC Pink.